A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye : ARISE-2

Trial Profile

A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye : ARISE-2

Completed
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2017

At a glance

  • Drugs Thymosin-beta-4 (Primary)
  • Indications Dry eyes
  • Focus Therapeutic Use
  • Acronyms ARISE-2
  • Sponsors ReGenTree
  • Most Recent Events

    • 31 Oct 2017 According to a ReGenTree Media Release, company plans meeting with the FDA based on the results of ARISE-2 trial.
    • 31 Oct 2017 Results presented in a ReGenTree Media Release.
    • 31 Oct 2017 Status changed from active, no longer recruiting to completed, according to a ReGenTree media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top